Trial Profile

A Phase 2b, Multi-Center, Randomized, Placebo-Controlled Double-Blind Study to Investigate the Safety and Efficacy of Once-Weekly MET097 in Participants With Obesity and Overweight (VESPER-1)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MET 097 (Primary)
Indications Obesity
Focus Therapeutic Use
Acronyms VESPER-1
Sponsors Metsera; Pfizer

Most Recent Events

13 Nov 2025 According to Pfizer media release, Metsera has been acquired and merged into Pfizer.
22 Oct 2025 Planned End Date changed from 1 Oct 2025 to 1 May 2026.
22 Oct 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com